Cancer stem cells in glioblastoma multiforme express components of the renin-angiotensin system, suggesting a potential novel therapeutic target through RAS modulation.
No takes yet. Share an insight, caveat, or question.
No immediate clinical role for RAS modulation in glioblastoma; leaves open targeting of SOX2-positive stem cells in future studies.
Bradshaw et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: